Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
Positive 12-month safety and efficacy data from ongoing Phase I/II clinical trial of ATSN-101 to be presented at 47th Annual...